drugset

drugset / Trial / NCT00768274

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274 ↗

Phase 1/2 Completed 72 enrolled Resverlogix Corp

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.

Timeline

Start: 2008-09
Primary completion: 2009-08
Completion: 2009-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apabetalone	Small molecule	—	Oral

Indications